1p36 deletion syndrome

Lore & Background

1p36 deletion syndrome results from the loss of genetic material at the outermost band of the short arm of chromosome 1. The deletion size ranges from approximately 1.5 million to over 10 million base pairs, with breakpoints most commonly found from 1p36.13 to 1p36.33. About 40% of breakpoints occur 3 to 5 million base pairs from the telomere. Most cases are de novo mutations, but 20% of patients inherit the deletion from a parent carrying a balanced translocation.

Reader's Guide

1p36 deletion syndrome is significant as the most common terminal deletion syndrome in humans, with a prevalence between 1 in 5,000 and 1 in 10,000 live births. Its symptoms vary widely depending on the exact deletion location, but commonly include moderate to severe intellectual disability, delayed speech and motor skills, seizures, hypotonia, and distinct facial features such as microcephaly, deep-set eyes, and a broad nasal bridge. Behavioral problems, including temper outbursts and self-injurious behavior, are frequent, and a significant proportion of affected individuals are on the autism spectrum. Diagnosis is typically confirmed by fluorescence in situ hybridization (FISH), chromosomal microarray, or karyotype analysis. There is no cure; treatment focuses on symptom management, including anti-seizure medications and feeding support via gastrostomy tubes. The syndrome underscores the importance of chromosomal microdeletions in developmental disorders and highlights the need for multidisciplinary care.

Did You Know?

• 1p36 deletion syndrome is the most common terminal deletion syndrome in humans.
• Approximately half of affected individuals have epilepsy or other seizures.
• Speech is severely affected; many children learn only a few words or have no speech at all.
• 20% of patients inherit the deletion from a parent who carries a balanced translocation.

Clinical Presentation & Developmental Trajectory

Children born with 1p36 deletion syndrome face a constellation of challenges spanning nearly every body system. Global developmental delays and failure to thrive are near-universal, with speech often the most severely affected domain—many individuals acquire only a few words or remain entirely nonverbal. Almost every child exhibits some degree of hypotonia, and motor milestones are consistently delayed. Neurologically, structural brain abnormalities such as agenesis of the corpus callosum, cortical atrophy, and ventriculomegaly are frequently observed, and roughly half of patients develop epilepsy or other seizure activity. Behavioral difficulties form a significant part of the clinical picture: temper outbursts, object-throwing, self-injurious actions like wrist-biting or head-banging, and screaming episodes are commonly reported. A notable share of affected individuals also fall on the autism spectrum, often displaying stereotyped movements. Feeding problems, including dysphagia and esophageal reflux, compound daily challenges. Vision is impaired in most cases, with farsightedness, nearsightedness, and strabismus being the most frequent findings, while rarer issues such as cataracts, optic atrophy, and optic nerve coloboma also occur. The syndrome additionally carries risk of congenital heart defects ranging from septal defects to tetralogy of Fallot, alongside skeletal anomalies like short fingers and abnormal finger curvature.

Genetic Architecture & Inheritance Patterns

1p36 deletion syndrome arises from the loss of a DNA segment at the outermost light band on the short arm (p) of chromosome 1, making it the most common terminal deletion syndrome in humans and one of the most prevalent deletion syndromes. Breakpoints are variable, most commonly falling between positions 1p36.13 and 1p36.33, with forty percent located three to five million base pairs from the telomere. The size of the deleted segment ranges widely, from approximately 1.5 million base pairs to more than ten million, and this variation in size and exact location helps explain why the clinical presentation differs from one patient to another. Most often, the deletion is a de novo mutation, arising spontaneously in the affected individual rather than being passed down. However, roughly twenty percent of patients inherit the condition from a parent who carries a balanced or symmetrical translocation—a rearrangement in which genetic material is swapped between chromosomes without net loss, so the parent is typically unaffected. The gene CASZ1, whose deletion in mouse models produces ventricular noncompaction, is implicated in the cardiac manifestations seen in some human patients, linking a particular genetic loss to a recognizable heart defect.

Diagnostic Pathway & Symptom Management

Because 1p36 deletion syndrome presents with a wide and variable array of signs, clinicians typically suspect the condition based on the combination of developmental delays, characteristic facial features, and other congenital anomalies observed in the child. Confirmation is then achieved through molecular cytogenetic testing, most commonly fluorescence in situ hybridization (FISH), though chromosomal microarray analysis and traditional karyotype examination are also valid diagnostic tools. Once a diagnosis is established, the therapeutic landscape is shaped by the absence of any curative intervention. Management is entirely supportive and symptom-directed. For the neurological manifestations, anti-seizure medications are a cornerstone of care for the roughly half of patients who experience epilepsy. Endocrine abnormalities also require appropriate pharmacological management. Feeding difficulties, which are common and can include dysphagia and esophageal reflux, are addressed with specialized assistive feeding devices or, in more severe cases, the placement of a gastrostomy tube to ensure adequate nutrition. The overarching goal of treatment is to alleviate the burden of individual symptoms—seizures, feeding problems, endocrine imbalances—rather than to reverse the underlying chromosomal deletion, which remains a permanent genetic change.

Epidemiology & the Landscape of a Rare Condition

Despite being the most common terminal deletion syndrome in humans and one of the most prevalent deletion syndromes, 1p36 deletion syndrome remains a relatively rare condition. The estimated incidence falls between one in 5,000 and one in 10,000 live births, a range that places it firmly in the rare-disease category. The true scale of affected individuals is difficult to pin down: between 1981 and 2015, only approximately 100 cases had been formally reported in the medical literature, a figure that likely underestimates the real population given the variability in presentation and the possibility of undiagnosed cases. The Genetic and Rare Disease Information Center at the National Institutes of Health estimates that fewer than 200,000 people in the United States are living with this disorder. This rarity carries practical consequences for research, clinical expertise, and family support networks. Because the deletion's size and exact breakpoint can vary considerably, no two patients present identically, complicating both diagnosis and the development of targeted therapies. As a congenital genetic disorder present from birth, the full spectrum of effects—intellectual disability, growth delay, seizures, sensory impairment, and structural malformations—unfolds over a lifetime.

Gallery